GSK plc (GSK) FinancialsGSKFinancialGSK plc

GSK plc (GSK) generates its revenue primarily from Commercial Operations, which accounts for 100.0% of total sales, equivalent to $11.27B. Understanding this concentration is critical for investors evaluating how GSK navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, GSK plc maintains a gross margin of 75.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.98%, while the net margin is 6.58%. These profitability ratios, combined with a Return on Equity (ROE) of 29.63%, provide a clear picture of how effectively GSK converts its operational activities into shareholder value.

In the context of the broader market, GSK competes directly with industry leaders such as REGN and SNY. With a market capitalization of $99.18B, it holds a significant position in the sector. When comparing efficiency, GSK's gross margin of 75.42% stands against REGN's 86.56% and SNY's 69.24%. Such benchmarking helps identify whether GSK plc is trading at a premium or discount relative to its financial performance.

GSK's gross margin is strong at 75.42%, and the net margin for the latest quarter is 6.58%. However, the company has faced fluctuations in net income, with a recent drop to $583 million in Q2 2026 from over $2 billion in Q3 2025.